EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety of anagliptin/metformin combination tablets evaluated by non‐inferiority between pre‐ and post‐serum lactic acid levels in Japanese patients with type 2 diabetes and moderate renal impairment ( AMELIO STUDY )

Hiroshi Kajio iD, Ryotaro Bouchi iD, Mitsuhisa Komatsu iD, Masanori Yamazaki, Daisuke Takarabe, Masahide Okamoto, Takahisa Tanaka, Toru Kitazawa, Hisayuki Katsuyama, Yasumichi Mori, Mitsuhiko Noda

Journal of Diabetes Investigation · 2026

DOI: 10.1111/jdi.70253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetes Investigation, 2026. Verfasst von Hiroshi Kajio und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Metformin, Lactic Acid, Hypoglycemic Agents. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanwa Kagaku Kenkyusho Co. Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/Introduction To investigate the safety of anagliptin/metformin combination tablets by evaluation of lactic acid levels in Japanese patients with type 2 diabetes and moderate renal impairment. Materials and Methods The participants of type 2 diabetes with creatinine‐based eGFR (eGFRcr) of ≥45 and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2MetforminLactic AcidHypoglycemic AgentsPyrimidinesRenal InsufficiencyBiomarkersHumansFemaleMaleTabletsMiddle AgedAgedJapanDrug Therapy, CombinationGlomerular Filtration RateFollow-Up StudiesPrognosisEast Asian People

Stichwörter der Autor:innen

Anagliptin/metforminModerate renal impairmentSerum lactic acid

Substanzen

MetforminLactic AcidTabletsHypoglycemic AgentsanagliptinPyrimidinesBiomarkers

Autor:innen und Institutionen

  • National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
  • Tokyo-Shinagawa Hospital, Tokyo, Japan.
  • Josai Clinic, Nakano Kyoritsu Hospital, Tokyo, Japan.
  • Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine, Shinshu University School of Medicine, Nagano, Japan.
  • Minamiishiki Central Clinic, Shizuoka, Japan.
  • Okamoto Clinic for Diabetes and Endocrinology, Oita, Japan.

ORCID-Profile: Hiroshi Kajio, Ryotaro Bouchi, Mitsuhisa Komatsu

Förderung

  • Sanwa Kagaku Kenkyusho Co. Ltd

Zitieren

APA

Kajio, H., Bouchi, R., Komatsu, M., Yamazaki, M., Takarabe, D., Okamoto, M., Tanaka, T., Kitazawa, T., Katsuyama, H., Mori, Y., & Noda, M. (2026). Safety of anagliptin/metformin combination tablets evaluated by non‐inferiority between pre‐ and post‐serum lactic acid levels in Japanese patients with type 2 diabetes and moderate renal impairment ( AMELIO STUDY ). Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.70253

Vancouver

Kajio H, Bouchi R, Komatsu M, Yamazaki M, Takarabe D, Okamoto M, et al. Safety of anagliptin/metformin combination tablets evaluated by non‐inferiority between pre‐ and post‐serum lactic acid levels in Japanese patients with type 2 diabetes and moderate renal impairment ( AMELIO STUDY ). Journal of Diabetes Investigation. 2026. doi:10.1111/jdi.70253

BibTeX
@article{Kajio2026,
  author = {Kajio, Hiroshi and Bouchi, Ryotaro and Komatsu, Mitsuhisa and Yamazaki, Masanori and Takarabe, Daisuke and Okamoto, Masahide and Tanaka, Takahisa and Kitazawa, Toru and Katsuyama, Hisayuki and Mori, Yasumichi and Noda, Mitsuhiko},
  title = {Safety of anagliptin/metformin combination tablets evaluated by non‐inferiority between pre‐ and post‐serum lactic acid levels in Japanese patients with type 2 diabetes and moderate renal impairment ( AMELIO STUDY )},
  journal = {Journal of Diabetes Investigation},
  year = {2026},
  doi = {10.1111/jdi.70253}
}
Kostenlos starten →